UK Faces Critical Shortage of Widely Prescribed Blood Pressure Medication

Health officials have issued an urgent warning regarding a critical shortage of Ramipril, a life-saving blood pressure medication relied upon by approximately six million Britons. The drug, prescribed around three million times monthly in the UK, is used to treat high blood pressure, kidney disease, and heart failure. It is also prescribed to patients who have experienced a heart attack to improve blood flow.

Under a newly implemented 'serious shortage protocol,' patients will be limited to a one-month supply of Ramipril at a time until October 30. This measure comes as pharmacies report experiencing the most severe medicine shortages they have ever encountered. Olivier Picard, chair of the National Pharmacy Association, stated that pharmacies are increasingly facing supply problems affecting everyday medicines.

Ramipril is a popular choice for patients with hypertension due to its once-daily dosage. Shortages of blood pressure drugs have been ongoing since the beginning of the year, partly attributed to instability in the Middle East, which has led to a series of serious shortage protocols being enacted.

In April, the Department of Health and Social Care first restricted Ramipril 1.25 mg, limiting pharmacists to prescribing only 28 tablets, despite many patients requiring the medication for life. By May, many pharmacies struggled to meet this demand, prompting a second protocol. Now, the limit is set at a one-month supply from both NHS and private pharmacies.

Traditionally, the shortage protocol prevents pharmacists from offering patients alternative medications without consulting their General Practitioner (GP). The National Pharmacy Association is now urging drug watchdogs to revise official guidance to allow pharmacists to make appropriate substitutions when necessary. Picard noted that while alternative medicines exist, their supplies must also be carefully managed by the government to meet the increased demand.

The fragility of the global medicine supply chain, exacerbated by international instability, is a significant factor in these shortages. The UK imports about 75 percent of its drugs, and many medications, even those sourced from Europe, are manufactured using ingredients from China, India, or the Middle East. Furthermore, government spending on medicines per patient in the UK is lower than in countries like France and Germany, potentially making the UK a less attractive market for pharmaceutical suppliers.

This shortage of Ramipril follows existing supply issues for other essential medications, including drugs for epilepsy, diabetes, antidepressants, and painkillers such as aspirin, codeine, and co-codamol.